Predicting time to nursing home placement based on activities of daily living scores - A modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil

Journal of Medical Economics

Volumn 12, Issue 2, 2009, Pages 98-103

  Hatoum, Hind T ^a,b   Thomas, Simu K ^c   Lin, Swu Jane ^a,b   Lane, Roger ^c   Bullock, Roger ^d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Hind T Hatoum and Company   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Activities of daily living; Alzheimer's disease; Cholinesterase inhibitor; Nursing home placement

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; RIVASTIGMINE;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DETERIORATION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; FEMALE; HEALTH CARE PLANNING; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NURSING HOME PATIENT; QUANTITATIVE ASSAY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE; SINGLE BLIND PROCEDURE; STATISTICAL MODEL;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DISEASE PROGRESSION; FEMALE; FORECASTING; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; NURSING HOMES; PATIENT TRANSFER; PHENYLCARBAMATES; PIPERIDINES; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PSYCHOMETRICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 67749106228     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903004039     Document Type: Article

References (28)

1. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;CD005593.
2. Jönsson L, Eriksdotter Jonhagen M, Kilander L, et al. Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry 2006;21:449-459. (Pubitemid 43757772)
3. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
4. Green C. Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis. Pharmacoeconomics 2007;25:735-750. (Pubitemid 47481639)
5. Quesada JJ, Ferrucci L, Calvani D, et al. Formal education as an effect modifier of the relationship between Mini-Mental State Examination score and IADLs disability in the older population. Aging (Milano) 1997;9:175-179. (Pubitemid 27305893)
6. Reed BR, Jagust WJ, Seab JP. Mental status as a predictor of daily function in progressive dementia. Gerontologist 1989;29:804-807.
7. Brodaty H, McGilchrist C, Harris L, Peters KE. Time until institutionalization and death in patients with dementia. Role of caregiver training and risk factors. Arch Neurol 1993;50:643-650.
8. Rice DP, Fox PJ, Max W, et al. The economic burden of Alzheimer's disease care. Health Aff (Millwood) 1993;12:164-176. (Pubitemid 23220072)
9. Teri L. Behavior and caregiver burden: behavioral problems in patients with Alzheimer disease and its association with caregiver distress. Alzheimer Dis Assoc Disord 1997;11(Suppl 4): S35-38. (Pubitemid 27453888)
10. Desai AK, Grossberg GT, Sheth DN. Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment. CNS Drugs 2004;18:853-875. (Pubitemid 39612016)
11. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005;21:1317-1327. (Pubitemid 41140736)
12. Gaugler JE, Duval S, Anderson KA, Kane RL. Predicting nursing home admission in the U.S: a meta-analysis. BMC Geriatr 2007;7:13. (Pubitemid 47058002)
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM IV), 4th Edn. Washington DC: American Psychiatric Association, 1994.
14. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944. (Pubitemid 14076461)
15. Panisset M, Roudier M, Saxton J, Boller F. Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol 1994;51:41-45.
16. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S33-39. (Pubitemid 27303108)
17. United States Agency for Health Care Policy and Research. Recognition and initial assessment of Alzheimer's disease and related dementias. Rockville, MD: U. S. Department of Health and Human Services Public Health Service Agency for Health Care Policy and Research, 1996:viii, 143 p.
18. Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001;16:653-666.
19. Fillit H, Hill J. Economics of dementia and pharmacoeconomics of dementia therapy. Am J Geriatr Pharmacother 2005;3:39-49.
20. Loveman E, Green C, Kirby J, et al. The clinical and costeffectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 2006;10: iii-iv, ix-xi, 1-160. (Pubitemid 43322990)
21. Takeda A, Loveman E, Clegg A, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry 2006;21:17-28. (Pubitemid 43141491)
22. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended): NICE technology appraisal guidance 111 (amended). London, UK: NICE, 2007.
23. Yaffe K, Fox P, Newcomer R, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 2002;287:2090-2097. (Pubitemid 34437344)
24. Stern Y, Tang MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997;277:806-812. (Pubitemid 27111316)
25. MetLife.The MetLife Market Survey of Nursing Home and Home Care Costs. Westport, CT: MetLife Mature Market Institute, 2004.
26. Curtis L, Netten A. Unit Costs of Health and Social Care 2006. Canterbury, UK: Personal Social Services Research Unit, University of Kent, 2006.
27. Mittelman MS, Haley WE, Clay OJ, Roth DL. Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease. Neurology 2006;67:1592-1599.
28. Argimon JM, Limon E, Vila J, Cabezas C. Health-related quality-of- life of care-givers as a predictor of nursing-home placement of patients with dementia. Alzheimer Dis Assoc Disord 2005;19:41-44. (Pubitemid 40940998)